Venlafaxine Tablet, Extended Release
NDC Package 70771-1649-3

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Venlafaxine tablets is classified as a

administered via oral route. This formulation utilizes a tablet, extended release delivery system. Marketed by Zydus Lifesciences Limited, this product is identified by NDC 70771-1649 and is authorized under FDA application ANDA215622.

Identification & Billing

NDC Package Code
70771-1649-3
Package Description
30 TABLET, EXTENDED RELEASE in 1 BOTTLE
Product Code
70771-1649
11-Digit Billing Format
70771164903
RxNorm Crosswalk
  • RxCUI: 808744 - venlafaxine HCl 150 MG 24HR Extended Release Oral Tablet
  • RxCUI: 808744 - 24 HR venlafaxine 150 MG Extended Release Oral Tablet
  • RxCUI: 808744 - venlafaxine 150 MG (as venlafaxine hydrochloride) 24 HR Extended Release Oral Tablet
  • RxCUI: 808744 - venlafaxine 150 MG 24 HR Extended Release Oral Tablet
  • RxCUI: 808748 - venlafaxine HCl 225 MG 24HR Extended Release Oral Tablet

Clinical Specifications

Proprietary Name
Venlafaxine
Non-Proprietary Name
Venlafaxine
Substance Name
Venlafaxine Hydrochloride
Dosage Form
Tablet, Extended Release - A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
VENLAFAXINE HYDROCHLORIDE 37.5 mg/1
Pharmacologic Class

Regulatory & Marketing

Labeler Name
Zydus Lifesciences Limited
Product Type
Human Prescription Drug
FDA Application #
ANDA215622
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-01-2022
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (70771-1649). Click a package code to view its specific billing and regulatory data.

70771-1649-1
100 TABLET, EXTENDED RELEASE in 1 BOTTLE
70771-1649-9
90 TABLET, EXTENDED RELEASE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70771-1649-3 identifies a specific commercial package of 30 tablet, extended release in 1 bottle of Venlafaxine, a human prescription drug labeled by Zydus Lifesciences Limited. This tablet, extended release is formulated for oral use and contains venlafaxine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Zydus Lifesciences Limited on September 01, 2022. The current certification is valid through December 31, 2026.

How is this Zydus Lifesciences Limited product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70771164903. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70771-1649-3
11-Digit CMS (5-4-2)
70771-1649-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.